Skip to Main Content

Paper Details

Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors.
Cancer Res
4
2023
CCNC, CDK8, CRISPR, Cas9, MAPK, MEK, RAS, RAS-driven malignancies, RAS-mutant neuroblastoma, advanced cancers, neuroblastoma, pro-growth gene, solid tumors
Author NameAffiliation
Gabriela AlexeDana-Farber Cancer Institute
Gabriela AlexeHarvard Medical School
Gabriela AlexeBroad Institute of MIT and Harvard
Gabriela AlexeDana-Farber Cancer Institute
Gabriela AlexeHarvard Medical School
Gabriela AlexeBroad Institute of MIT and Harvard
Nathanael S Grayand Stanford Cancer Institute, Stanford University
Nathanael S Grayand Stanford Cancer Institute, Stanford University
Federica PiccioniBroad Institute of MIT and Harvard
Kimberly StegmaierBroad Institute of MIT and Harvard
Kimberly StegmaierHarvard Medical School
Kimberly StegmaierBoston Children's Hospital
Kimberly StegmaierDana-Farber Cancer Institute
Kimberly StegmaierDana-Farber Cancer Institute
Kimberly StegmaierBroad Institute of MIT and Harvard
Kimberly StegmaierHarvard Medical School
Kimberly StegmaierBoston Children's Hospital
  • 1 - 17

Datasets

Release 1.2